Physician profile
Daniel E Schneider
NPI 1902061260
$1,048.75
in general payments reported to CMS, 2019-2025
19 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.68 · 2020: $55.74 · 2021: $187 · 2022: $235 · 2023: $362 · 2024: $31.33 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.76 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $82.60 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $76.82 | 2020-2022 | |
| Amgen INC. | $76.42 | 2021-2023 | Prolia, Evenity, Repatha |
| Novo Nordisk INC | $54.26 | 2019-2025 | Wegovy |
| Abbott Laboratories | $36.95 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Biotech, INC. | $35.19 | 2025 | Erleada |
| Boston Scientific Corporation | $33.19 | 2023 | Lithovue, Watchman Flx |
| Resmed Corp | $22.68 | 2025 | |
| Antares Pharma, INC. | $22.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.37 | 2022 | |
| Medtronic, INC. | $17.13 | 2024 | Kyphon Express II Kyphopak Tray |
| Sumitomo Pharma America, INC. | $14.68 | 2025 | Gemtesa |
| Acadia Pharmaceuticals INC | $14.63 | 2019 | |
| Glaxosmithkline, LLC. | $14.14 | 2023 | Trelegy Ellipta |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13.51 | 2023 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $13.08 | 2021 | |
| Dexcom, INC. | $11.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.